Your browser doesn't support javascript.
loading
The effect of treatment on quality of life in patients with acromegaly: a prospective study.
Wolters, T L C; Roerink, S H P P; Sterenborg, R B T M; Wagenmakers, M A E M; Husson, O; Smit, J W A; Hermus, A R M M; Netea-Maier, R T.
Afiliación
  • Wolters TLC; Division of Endocrinology, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Roerink SHPP; Division of Endocrinology, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Sterenborg RBTM; Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands.
  • Wagenmakers MAEM; Division of Endocrinology, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Husson O; Division of Endocrinology, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Smit JWA; Department of Internal Medicine, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Hermus ARMM; Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Netea-Maier RT; Department of Clinical Studies, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
Eur J Endocrinol ; 182(3): 319-331, 2020 Mar.
Article en En | MEDLINE | ID: mdl-31958318
ABSTRACT

OBJECTIVE:

Acromegaly has a negative influence on health-related quality of life (HRQoL). Previous studies provide limited information on the course of HRQoL during treatment. This study aims to assess the effect of treatment on the course of HRQoL at six predefined time points.

DESIGN:

This prospective study examines HRQoL in treatment-naive patients before and during the first 2.5 years of acromegaly treatment.

METHODS:

Therapy-naive acromegaly patients completed three validated questionnaires (RAND-36, AcroQoL, and the Appearance Self-Esteem (ASE)) at six predetermined time points before, during, and after treatment. Outcomes were correlated to IGF1 levels and disease control status.

RESULTS:

Twenty-seven acromegaly patients completed the questionnaires at all time points. After treatment, all patients had controlled acromegaly. Scores of RAND-36 domains General health, Vitality and Health change, and all AcroQoL dimensions (except for Relations) improved during treatment (P ≤ 0.003); the largest changes were detected during the first year. Gender influenced HRQoL scores, since AcroQoL scores significantly improved in males but not in females. Over time, IGF1 levels were negatively correlated with HRQoL. After 2.5 years of follow-up, HRQoL of controlled patients was still lower than in the general population.

CONCLUSION:

HRQoL of acromegaly patients was considerably reduced at diagnosis. Disease control was associated with an improvement of HRQoL scores. Males showed a more pronounced improvement than females. The largest changes were detected in the first year of treatment. However, HRQoL during and after treatment remained impaired in acromegaly patients, emphasizing the need of additional support.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Calidad de Vida / Acromegalia Tipo de estudio: Observational_studies / Qualitative_research / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Endocrinol Asunto de la revista: ENDOCRINOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Calidad de Vida / Acromegalia Tipo de estudio: Observational_studies / Qualitative_research / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Endocrinol Asunto de la revista: ENDOCRINOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos